浆膜下与黏膜下碳纳米颗粒引导腹腔镜胃癌根治术的随机临床试验
本研究为随机临床试验,比较浆膜下与黏膜下注射碳纳米颗粒在腹腔镜胃癌根治术中的淋巴结清扫效果、围术期安全性和成本。结果显示浆膜下组清扫淋巴结数目更多、手术时间更短、示踪相关成本更低,且诊断价值更优,围术期安全性相当。
要点
- 浆膜下注射碳纳米颗粒可增加淋巴结清扫数目和转移淋巴结检出数。
- 浆膜下组手术时间更短,示踪相关成本更低。
- 两组围术期安全性相当,浆膜下组诊断价值更优。
核心结论
- 在腹腔镜胃癌根治术中,浆膜下注射碳纳米颗粒在淋巴结清扫方面优于黏膜下注射,围术期安全性相当且示踪相关成本更低。
研究设计与样本
- 随机临床试验,纳入可切除胃癌患者(cT1-4a, cNany, cM0),随机分为浆膜下组(49例)和黏膜下组(50例),均行腹腔镜D2淋巴结清扫术。
主要发现
- 浆膜下组清扫淋巴结数目显著多于黏膜下组(36.6 ± 1.4 vs 32.2 ± 1.4,P = .02)。
- 浆膜下组清扫转移淋巴结数目显著多于黏膜下组(3.1 ± 0.6 vs 1.5 ± 0.5,P = .04)。
- 浆膜下组手术时间显著短于黏膜下组(150.9 ± 3.0分钟 vs 194.7 ± 6.2分钟,P < .001)。
- 浆膜下组示踪相关成本显著低于黏膜下组(1,824.8 ± 110.9 vs 2,395.5 ± 112.5[人民币],P < .001),非示踪相关成本两组相似。
- 浆膜下组对转移站或淋巴结的诊断价值(敏感性、特异性、阳性预测值、阴性预测值)优于黏膜下组。
临床怎么用
- 对于拟行腹腔镜胃癌根治术的患者,可考虑采用浆膜下注射碳纳米颗粒进行淋巴结示踪,以提高淋巴结清扫效果并降低示踪相关成本。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To compare the efficacy in lymph node dissection, perioperative safety, and cost of subserosal and submucosal administration of carbon nanoparticles in laparoscopic radical gastrectomy for gastric cancer. METHODS: This was a randomized clinical trial. Patients with potentially resectable gastric cancer (cT1-4a, cNany, cM0) were randomized into subserosal or submucosal groups. Laparoscopic D2 lymphadenectomy was performed for each patient. RESULTS: Between September 2023 and August 2024, 49 patients were enrolled in the subserosal group and 50 patients were enrolled in the submucosal group. The number of retrieved lymph nodes in the subserosal group was significantly greater than that in the submucosal group (36.6 ± 1.4 vs 32.2 ± 1.4, P = .02). The number of retrieved metastatic lymph nodes in the subserosal group was also significantly greater than that in the submucosal group (3.1 ± 0.6 vs 1.5 ± 0.5, P = .04). The duration of surgery in the subserosal group was shorter than that in the submucosal group (150.9 ± 3.0 minutes vs 194.7 ± 6.2 minutes, P < .001). The tracing-related cost in the subserosal group was lower than that in the submucosal group (1,824.8 ± 110.9 vs 2,395.5 ± 112.5 [in Chinese currency], P < .001), whereas the tracing-excluded cost was similar between groups. Diagnostic values, including sensitivity, specificity, positive predictive value, and negative predictive value for metastatic stations or lymph nodes, of the subserosal approach were superior to those of the submucosal approach. CONCLUSION: Subserosal is superior to submucosal administration of carbon nanoparticles in lymph node dissection with comparable perioperative safety and decreased tracing-related cost in laparoscopic radical gastrectomy for gastric cancer. TRIAL REGISTRATION: ISRCTN11247387 (https://doi.org/10.1186/ISRCTN11247387).
引用
- Liu S, Song P, Hu Q, et al. Efficacy and safety of subserosal versus submucosal carbon nanoparticle-guided laparoscopic radical gastrectomy (DANCE-04): A randomized clinical trial. Surgery. 2025. PMID: 40393912. doi:10.1016/j.surg.2025.109398
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。